PIC1 Injection Therapy for Relapsed/Refractory B-NHL

Sponsor
Chongqing Precision Biotech Co., Ltd
Study ID
NCT07456371
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • PIC1 Injection — BIOLOGICAL
    Three dose groups (1.0×10\^9 TU, 2.0×10\^9 TU, 4.0×10\^9 TU) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Study Details

This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.

Key Dates

First listed
Mar 6, 2026
Start date
Mar 31, 2026
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Feb 28, 2029

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PIC1 Injection

Primary Outcome Measure

Incidence of Adverse Events (AEs) after infusion [ Time Frame: 1 month ]

Central Contacts

Related Studies